[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053228":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":147,"collaborators":19,"id":149,"slug":19,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":19,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":19,"enrollmentInfo":157,"targetDuration":19,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":166,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AZD0120","EXPERIMENTAL","AZD0120 will be administrated in one infusion",[13],"Biological: AZD0120",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","AZD0120 is a BCMA\u002FCD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[27,40,50,59,68,77,86,95,104,112,121,130,138],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":19},"Research Site","WITHDRAWN","Phoenix","Arizona","85054","United States",{"type":35,"coordinates":36},"Point",[37,38],-112.07404,33.44838,{"lat":38,"lon":37},{"facility":28,"status":41,"city":42,"state":43,"zip":44,"country":33,"cosmosGeoPoint":45,"geoPoint":49,"contacts":19},"RECRUITING","Duarte","California","91010",{"type":35,"coordinates":46},[47,48],-117.97729,34.13945,{"lat":48,"lon":47},{"facility":28,"status":41,"city":51,"state":52,"zip":53,"country":33,"cosmosGeoPoint":54,"geoPoint":58,"contacts":19},"Denver","Colorado","80218",{"type":35,"coordinates":55},[56,57],-104.9847,39.73915,{"lat":57,"lon":56},{"facility":28,"status":41,"city":60,"state":61,"zip":62,"country":33,"cosmosGeoPoint":63,"geoPoint":67,"contacts":19},"Tampa","Florida","33612",{"type":35,"coordinates":64},[65,66],-82.45843,27.94752,{"lat":66,"lon":65},{"facility":28,"status":41,"city":69,"state":70,"zip":71,"country":33,"cosmosGeoPoint":72,"geoPoint":76,"contacts":19},"Atlanta","Georgia","30322",{"type":35,"coordinates":73},[74,75],-84.38798,33.749,{"lat":75,"lon":74},{"facility":28,"status":41,"city":78,"state":79,"zip":80,"country":33,"cosmosGeoPoint":81,"geoPoint":85,"contacts":19},"Iowa City","Iowa","52242",{"type":35,"coordinates":82},[83,84],-91.53017,41.66113,{"lat":84,"lon":83},{"facility":28,"status":29,"city":87,"state":88,"zip":89,"country":33,"cosmosGeoPoint":90,"geoPoint":94,"contacts":19},"Rochester","Minnesota","55905",{"type":35,"coordinates":91},[92,93],-92.4699,44.02163,{"lat":93,"lon":92},{"facility":28,"status":41,"city":96,"state":97,"zip":98,"country":33,"cosmosGeoPoint":99,"geoPoint":103,"contacts":19},"St Louis","Missouri","63110",{"type":35,"coordinates":100},[101,102],-90.19789,38.62727,{"lat":102,"lon":101},{"facility":28,"status":41,"city":105,"state":105,"zip":106,"country":33,"cosmosGeoPoint":107,"geoPoint":111,"contacts":19},"New York","10016",{"type":35,"coordinates":108},[109,110],-74.00597,40.71427,{"lat":110,"lon":109},{"facility":28,"status":41,"city":113,"state":114,"zip":115,"country":33,"cosmosGeoPoint":116,"geoPoint":120,"contacts":19},"Nashville","Tennessee","37203",{"type":35,"coordinates":117},[118,119],-86.78444,36.16589,{"lat":119,"lon":118},{"facility":28,"status":29,"city":122,"state":123,"zip":124,"country":33,"cosmosGeoPoint":125,"geoPoint":129,"contacts":19},"Dallas","Texas","75235",{"type":35,"coordinates":126},[127,128],-96.80667,32.78306,{"lat":128,"lon":127},{"facility":28,"status":41,"city":131,"state":123,"zip":132,"country":33,"cosmosGeoPoint":133,"geoPoint":137,"contacts":19},"Houston","77030",{"type":35,"coordinates":134},[135,136],-95.36327,29.76328,{"lat":136,"lon":135},{"facility":28,"status":41,"city":139,"state":140,"zip":141,"country":33,"cosmosGeoPoint":142,"geoPoint":146,"contacts":19},"Charlottesville","Virginia","22903",{"type":35,"coordinates":143},[144,145],-78.47668,38.02931,{"lat":145,"lon":144},{"type":148,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100053228",false,"NCT07073547","A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)","Inclusion Criteria:\n\nAge:\n\n* Males and females ≥18 years of age at the time of consent\n\nType of Participant and Disease Characteristics:\n\n* Participant must have documented diagnosis of MM per IMWG diagnostic criteria\n* ECOG performance status of 0 or 1.\n* Adequate organ and bone marrow function.\n\nFor NDMM participants:\n\n* Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prior anti- myeloma therapy (no more than 2 cycles of induction therapy before enrollment are acceptable)\n* For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and a maximum of 6 cycles of induction therapy completed prior to screening\n* Classified as high-risk MM\n\nFor Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants:\n\n* Have received and failed 1 or 2 lines of anti-myeloma therapy\n* Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as part of their previous therapy\n* Have documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria within 1 year of starting treatment, or on or within 6 months of completing treatment of the subject's last line of anti-myeloma therapy, or have confirmed progressive disease within 6 months prior to screening and who are subsequently determined to be refractory or non-responsive to their most recent anti-myeloma treatment regimen\n\nGeneral Exclusion Criteria:\n\n* Have received prior treatment with CAR T therapy directed at any target\n* Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma\n* Active or history of plasma cell leukemia at the time of screening\n* Seropositive for human immunodeficiency virus (HIV)\n* Active Hepatitis B infection\n* Active Hepatitis C infection\n* Serious underlying medical condition","ALL","18 Years",{"count":158,"type":159},40,"ESTIMATED","INTERVENTIONAL",[162],"PHASE1","This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).",[165],"Multiple Myeloma",[167,168,169,170],"Multiple myeloma","BCMA","CD19","CAR-T","2026-07-10",{"date":173,"type":174},"2026-07-13","ACTUAL",{"date":176,"type":174},"2025-07-31",{"date":178,"type":159},"2028-05-26",{"name":5,"class":6},13]